Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Consensus Rating of “Hold” by Analysts

Alphatec Holdings, Inc. (NASDAQ:ATECGet Rating) has been given an average recommendation of “Hold” by the nine ratings firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $19.00.

Several equities research analysts have recently issued reports on ATEC shares. Piper Sandler decreased their price objective on Alphatec from $22.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, March 2nd. Zacks Investment Research cut Alphatec from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th. HC Wainwright lifted their target price on Alphatec from $19.00 to $20.00 in a report on Friday, May 6th. Finally, StockNews.com started coverage on Alphatec in a report on Thursday, March 31st. They issued a “sell” rating on the stock.

Alphatec stock opened at $7.65 on Tuesday. The company has a debt-to-equity ratio of 7.78, a quick ratio of 2.37 and a current ratio of 2.62. The stock has a fifty day moving average of $10.81 and a two-hundred day moving average of $11.02. The company has a market capitalization of $778.46 million, a price-to-earnings ratio of -4.64 and a beta of 1.57. Alphatec has a fifty-two week low of $7.28 and a fifty-two week high of $16.47.

Alphatec (NASDAQ:ATECGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The medical technology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.14). Alphatec had a negative return on equity of 147.10% and a negative net margin of 60.83%. The business had revenue of $70.93 million for the quarter, compared to analyst estimates of $67.72 million. On average, analysts forecast that Alphatec will post -1.31 EPS for the current fiscal year.

In other Alphatec news, major shareholder Jennifer N. Pritzker bought 4,000 shares of the company’s stock in a transaction dated Friday, May 13th. The shares were acquired at an average cost of $7.96 per share, with a total value of $31,840.00. Following the completion of the transaction, the insider now owns 46,200 shares in the company, valued at $367,752. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Patrick Miles sold 100,000 shares of Alphatec stock in a transaction dated Wednesday, May 18th. The stock was sold at an average price of $8.34, for a total value of $834,000.00. Following the sale, the chief executive officer now directly owns 5,858,634 shares in the company, valued at $48,861,007.56. The disclosure for this sale can be found here. In the last 90 days, insiders have acquired 9,100 shares of company stock worth $83,024 and have sold 206,730 shares worth $1,695,968. Insiders own 34.38% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. LPL Financial LLC increased its position in shares of Alphatec by 17.7% during the third quarter. LPL Financial LLC now owns 127,629 shares of the medical technology company’s stock worth $1,556,000 after acquiring an additional 19,154 shares during the last quarter. Advisor Group Holdings Inc. increased its holdings in Alphatec by 65.4% in the fourth quarter. Advisor Group Holdings Inc. now owns 35,787 shares of the medical technology company’s stock valued at $408,000 after buying an additional 14,153 shares during the last quarter. Deerfield Management Company L.P. Series C increased its holdings in Alphatec by 5.7% in the third quarter. Deerfield Management Company L.P. Series C now owns 3,594,829 shares of the medical technology company’s stock valued at $43,821,000 after buying an additional 192,445 shares during the last quarter. Voya Investment Management LLC increased its holdings in Alphatec by 4.6% in the third quarter. Voya Investment Management LLC now owns 27,702 shares of the medical technology company’s stock valued at $338,000 after buying an additional 1,219 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in Alphatec by 945.3% in the third quarter. Point72 Asset Management L.P. now owns 3,062,091 shares of the medical technology company’s stock valued at $37,327,000 after buying an additional 2,769,149 shares during the last quarter. 53.52% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Company Profile (Get Rating)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement.

Read More

Analyst Recommendations for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.